POAI — Predictive Oncology Share Price
0.000.00%
Last trade - 00:00- $9.47m
- $8.73m
- $1.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -793.29% | ||
| Return on Equity | -269.23% | ||
| Operating Margin | -673.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.25 | 1.42 | 1.51 | 1.63 | 1.62 | 9.33 | 15.45 | 2.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Directors
- J. Melville Engle CHM (72)
- Carl Schwartz PRE (79)
- Robert Myers CFO (66)
- Christina Jenkins DRC
- Raymond Vennare DRC
- Nancy Chung-Welch IND (61)
- Daniel Handley IND (61)
- Chuck Nuzum IND (73)
- Gregory St.Clair IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 11th, 2013
- Public Since
- December 18th, 2009
- No. of Shareholders
- 154
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 8,931,621
- Address
- 91 43RD STREET, SUITE 110, PITTSBURGH, 15201
- Web
- https://predictive-oncology.com/
- Phone
- +1 4124321500
- Auditors
- KPMG
Upcoming Events for POAI
Q2 2025 Predictive Oncology Inc Earnings Release
Similar to POAI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Predictive Oncology share price?
As of Today at 22:44 UTC, shares in Predictive Oncology are trading at $1.06. This share price information is delayed by 15 minutes.
How has the Predictive Oncology share price performed this year?
Shares in Predictive Oncology last closed at $1.06 and the price had moved by -36.14% over the past 365 days. In terms of relative price strength the Predictive Oncology share price has underperformed the S&P500 Index by -41.06% over the past year.
What are the analyst and broker recommendations for Predictive Oncology?
The overall consensus recommendation for Predictive Oncology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Predictive Oncology dividend yield?
Predictive Oncology does not currently pay a dividend.
Does Predictive Oncology pay a dividend?
Predictive Oncology does not currently pay a dividend.
When does Predictive Oncology next pay dividends?
Predictive Oncology does not currently pay a dividend.
How do I buy Predictive Oncology shares?
To buy shares in Predictive Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Predictive Oncology?
As of the previous close price of $1.06, shares in Predictive Oncology had a market capitalisation of $9.47m.
Where are Predictive Oncology shares listed?
Here are the trading details for Predictive Oncology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: POAI
What kind of share is Predictive Oncology?
Based on an overall assessment of its quality, value and momentum Predictive Oncology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Predictive Oncology share price forecast for 2025?
The analyst consensus target price for shares in Predictive Oncology is $3.00. That is 183.02% above the last closing price of $1.06.
Analysts covering Predictive Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$0.13 for the next financial year.
Find out moreWhat is the trend in the Predictive Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Predictive Oncology. Over the past six months, its share price has outperformed the S&P500 Index by +33.64%.
As of the last closing price of $1.06, shares in Predictive Oncology were trading +3.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Predictive Oncology PE Ratio?
The Predictive Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Predictive Oncology?
Predictive Oncology's management team is headed by:
- J. Melville Engle - CHM
- Carl Schwartz - PRE
- Robert Myers - CFO
- Christina Jenkins - DRC
- Raymond Vennare - DRC
- Nancy Chung-Welch - IND
- Daniel Handley - IND
- Chuck Nuzum - IND
- Gregory St.Clair - IND